Ikeda, Sadakatsu
Goodman, Aaron M
Cohen, Philip R
Jensen, Taylor J
Ellison, Christopher K
Frampton, Garrett
Miller, Vincent
Patel, Sandip P
Kurzrock, Razelle
Article History
Received: 8 June 2016
Revised: 29 August 2016
Accepted: 19 September 2016
First Online: 19 October 2016
Competing interests
: AMG receives fellowship funding from Pfizer. TJJ and CKE are employees and shareholders of Sequenom. GF and VM are employees and equity holders of Foundation Medicine. SPP receives research funding from: MedImmune, Pfizer, Amgen, Xcovery, Genentech, Incyte, and Lilly. He receives consulting fees from: Lilly. He receives speaking fees from: Boehringer Ingelheim. RK receives research funding from Genentech, Merck, Serono, Pfizer, Sequenom, Foundation Medicine, and Guardant, as well as consultant fees from Sequenom, X Biotech, and Actuate Therapeutics and an ownership interest in Novena, Inc and Curematch Inc. The remaining authors declare no conflict of interest.